<DOC>
	<DOCNO>NCT00002426</DOCNO>
	<brief_summary>The purpose study see safe effective give experimental anti-HIV drug , adefovir dipivoxil ( ADV ) , combination anti-HIV drug ( HAART ) patient viral load ( level HIV blood ) 50 400 copies/ml .</brief_summary>
	<brief_title>A Study Safety Effectiveness Adefovir Dipivoxil Combination With Anti-HIV Therapy ( HAART ) HIV-Positive Patients</brief_title>
	<detailed_description>Patients randomize 1 2 arm 2:1 ratio . Approximately 260 patient receive ADV approximately 130 patient receive placebo . Patients receive ADV placebo addition L-carnitine current stable HAART regimen . Each patient receive blind study medication 48 week evaluate Weeks 16 , 24 , 48 . Patients reach primary endpoint virologic failure prior Week 48 may continue blind study medication receive open-label ADV investigator 's discretion . In case , patient continue study visit per original visit schedule . Virologic failure define 2 consecutive HIV-1 RNA measurement , baseline , 400 copies/ml ( measure Roche Amplicor HIV-1 Monitor UltraSensitive assay ) drawn least 14 day apart . All patient complete study visit without treatment-limiting ADV toxicity may continue open-label ADV Maintenance Phase discretion principal investigator .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<criteria>Inclusion Criteria You may eligible study : Are HIVpositive . Have stable HAART regimen consist least 3 antiretroviral drug least 16 week prior study entry . Have CD4 count 50 cells/mm3 . Have viral load great 50 less equal 400 copies/ml within 14 day prior study entry . Have least 1 additional viral load past less equal 400 copies/ml current stable HAART regimen .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 1999</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>VX 478</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
</DOC>